PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 25, 2026Breast Cancer Research and Treatment1 citationsOpen Access

Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study

MSMichelle SterpiNDNechama DreyfusYLYungtai Lo

Key Points

  • To evaluate how immune-related adverse events affect treatment response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer patients.
  • Conducted a retrospective study at a single institution
  • Analyzed the impacts of immune-related adverse events on treatment outcomes
  • Examined variations in response based on age and race
  • Immune-related adverse events may indicate better treatment responses
  • Racial and age differences in treatment response were observed
  • Findings underscore the need for inclusion of diverse patient populations in immunotherapy research

Abstract

IrAEs may serve as a surrogate for treatment response to neoadjuvant chemoimmunotherapy in early TNBC. Additionally, racial and age-based differences in treatment response suggest underlying immunologic or biologic variation. These findings highlight the importance of diverse cohort representation in immunotherapy studies and warrant validation in prospective trials.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sterpi et al. (2026) studied this question.

synapsesocial.com/papers/699e911bf5123be5ed04e6ebhttps://doi.org/10.1007/s10549-026-07930-8
Ask AI
Helpful
Bookmark
Share
View Full Paper